Mechanisms of resistance to macrolides and lincosamides: Nature of the resistance elements and their clinical implications

Clinical Infectious Diseases

Volumn 34, Issue 4, 2002, Pages 482-492

  Leclercq, Roland ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LINCOSAMIDE; MACROLIDE; PENICILLIN G;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; DRUG INACTIVATION; DRUG TRANSPORT; ERADICATION THERAPY; GRAM POSITIVE BACTERIUM; HUMAN; METHYLATION; NONHUMAN; OTITIS MEDIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; R FACTOR; RIBOSOME; STREPTOCOCCUS INFECTION; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; DNA METHYLATION; DNA, RIBOSOMAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); VARIATION (GENETICS);

EID: 0037083024     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324626     Document Type: Article

References (72)

1. Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin-resistant and susceptible pathogens
2. Erythromycin resistance by ribosome modification
3. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants
4. The sensitivity of staphylococcal and other wound bacteria to erythromycin
5. Group A streptococcus resistant to erythromycin and lincomycin
6. Insights into erythromycin action from studies of its activity as inducer of resistance
7. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci
8. Clindamycin therapy of Staphylococcus aureus endocarditis: Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin
9. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance
10. A complex attenuator regulates inducible resistance to macrolides, lincosamides, and streptogramin type B antibiotics in Streptococcus sanguis
11. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin
12. Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides
13. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin
14. Erythromycin resistance genes in group A streptococci in Finland: The Finnish Study Group for Antimicrobial Resistance
15. Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece
16. Macrolide resistance conferred by base substitutions in 23S rRNA
17. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America
18. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family
19. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university, hospitals
20. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes
21. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
22. Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae
23. Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm[B] and mef[A]) in South Africa
24. Erythromycin resistance genes in group A streptococci of different geographical origins: The Macrolide Resistance Study Group
25. A plasmid that encodes three genes for resistance to macrolide antibiotics in Staphylococcus aureus
26. Phenotypic expression and genetic heterogeneity of lincosamide inactivation in Staphylococcus spp.
27. A new resistance gene, linB, conferring resistance to lincosamides by nucleotidylation in Enterococcus faecium HM1025
28. Pneumococcal macrolide resistance: Myth or reality?
29. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy
30. Intraphagocytic location of macrolides
31. Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci
32. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome
33. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children
34. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
35. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: Influence of macrolide resistance on clinical and microbiological outcomes
36. Erythromycin resistance in Streptococcus pyogenes in Italy
37. Resistance to erythromycin in group A streptococci
38. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis
39. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
40. Streptococcus pneumoniae in the USA: In vitro susceptibility and pharmacodynamic analysis
41. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment
42. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999
43. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study
44. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis collected from five centers in Brazil, 1997-98
45. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme
46. The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project
47. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Belgium-update (1994-98)
48. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
49. Pneumococcal antibiotic resistance: Results from 21 regional registries for 1999 [French]
50. Antimicrobial susceptibility of invasive Streptococcus pneumoniae in Italy by agar dilution method and E test
51. A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal
52. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
53. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid
54. High prevalence of antibiotic resistance of common pathogenic bacteria in Taiwan
55. Prevalence and phenotypes of erythromycin-resistant Streptococcus pneumoniae in Shanghai, China
56. Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities
57. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa
58. The Alexander Project, 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
59. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
60. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995
61. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997)
62. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: Examination of 301 strains isolated in the United States between 1994 and 1997
63. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California
64. Phenotypic and genotypic characterization of macrolide-resistant group A streptococcus strains in the province of Quebec, Canada
65. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile
66. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates
67. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland
68. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients
69. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: Results of a Spanish multicentre study in 1998
70. The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea
71. Prevalence of polyclonal mefA-containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan
72. Use of clindamycin disks to detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children